Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 11Prostatic Neoplasms 7Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Small Cell Lung Carcinoma 2Fallopian Tube Neoplasms 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 43venetoclax 30Cytarabine 25fludarabine 22fludarabine phosphate 17Azacitidine 16Mycophenolic Acid 13Whole-Body Irradiation 12Dexamethasone 12Rituximab 11Busulfan 11ruxolitinib 10Vincristine 10Methotrexate 10Etoposide 10Tacrolimus 9Mercaptopurine 9Daunorubicin 9Prednisone 8Filgrastim 8Dasatinib 8ibrutinib 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7Decitabine 7pegaspargase 6blinatumomab 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × talazoparib × 1 year × Clear all
NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
13 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡